Heron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Heron Therapeutics

10/08/2026 14:31

Heron Therapeutics Inc HRTX.OQ reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -2 cents.  The mean expectation of two analysts for the quarter was for earnings of one cent per share. 
Revenue rose 1.3% to $37.67 million from a year ago; analysts expected $42.20 million. 
Heron Therapeutics Inc's reported EPS for the quarter was a loss of 3 cents​.
The company reported quarterly net income of $30 thousand.
Heron Therapeutics Inc shares had risen by 15.0% this quarter and lost 62.2% so far this year.
FORECAST CHANGES
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Heron Therapeutics Inc is $2.50, about 80.4% above its last closing price of $0.49
This summary was machine generated from LSEG data August 10 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.01
-0.03
Missed
Mar. 31 2026 
-0.01
-0.04
Missed
Dec. 31 2025 
-0.02
-0.02
Met
Sep. 30 2025 
-0.01
-0.04
Missed